GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

NCT00707031 on ClinicalTrials.gov · last registry update 2016-12-02

Finished November 2010, after enrolling 639 people. Primary outcome, as filed: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: exenatide
Bydureon, Byetta
Sponsor: Sanofi
Sponsor type: Industry
Enrollment: 639
Started: 2008-06
Primary completion: 2010-11 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.